This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wellington, M.
Right arrow Articles by Haidaris, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wellington, M.
Right arrow Articles by Haidaris, C. G.

 Previous Article  |  Next Article 

Infection and Immunity, December 2003, p. 7228-7231, Vol. 71, No. 12
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.12.7228-7231.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Enhanced Phagocytosis of Candida Species Mediated by Opsonization with a Recombinant Human Antibody Single-Chain Variable Fragment

Melanie Wellington,1,2 Joseph M. Bliss,1,{dagger} and Constantine G. Haidaris2,3*

Department of Pediatrics,1 Department of Microbiology and Immunology,2 Center for Oral Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York 146423

Received 29 July 2003/ Returned for modification 8 August 2003/ Accepted 15 September 2003


arrow
ABSTRACT
 
Specific antibody opsonization significantly enhances the level of phagocytosis of Candida in the absence of complement. Furthermore, we have described a system using a recombinant human antibody single-chain variable fragment that allows a comparative study of phagocytosis of multiple Candida species opsonized via a common antigen.


arrow
TEXT
 
Candidiasis, the most common systemic fungal infection, is increasing in frequency (18). Antibody can play an important role in the host response to Candida (8, 9); however, polyclonal antibody responses may include antibodies detrimental to the host (3). While phagocytes are considered the primary anti-Candida effector cells (13, 27), previous studies on the effects of antibody opsonization on phagocytosis were performed in the presence of complement (4, 10, 15, 19). Specifically targeting organisms to phagocyte Fc receptors (FcR), however, has been shown to benefit the host by augmenting phagocytosis, organism killing, and stimulation of the adaptive immune system (1, 5, 6, 26), whereas phagocytosis via complement has been associated with suppressed immune responses (6). Furthermore, although infections caused by Candida species other than Candida albicans are now in the majority (16, 20, 21, 28), little is known about the effects of antibody on the host response to non-albicans Candida.

We previously described a human single-chain variable fragment (scFv), scFv{lambda}2-18, that recognizes both C. albicans and non-albicans species (2, 7). Herein, we investigated the ability of scFv{lambda}2-18 to target FcR and mediate phagocytosis. scFv{lambda}2-18, which recognizes cell surface mannans (data not shown) on blastoconidia and filamentous forms of Candida, and a control scFv, scFv5 (2), which recognizes a protein antigen expressed only on filamentous Candida, were prepared using the method of Kipriyanov et al. (11). Because scFv does not contain an Fc region, but does contain the FLAG epitope tag (14), organisms were opsonized with a three-layer complex consisting of 10 µg of scFv{lambda}2-18 per ml, 10 µg of M2 anti-FLAG mouse monoclonal antibody per ml (Sigma-Aldrich, St. Louis, Mo.), and a 1:250 dilution of an immunoglobulin G (IgG) fraction of rabbit anti-mouse polyclonal antiserum (Jackson ImmunoResearch, West Grove, Pa.). For comparison, organisms were opsonized with a 1:250 dilution of an IgG fraction of rabbit anti-C. albicans polyclonal antiserum (pIgG; Accurate Chemical, Inc., Westbury, N.Y.).

To demonstrate that the scFv{lambda}2-18 complex could target Candida to FcR, opsonized blastoconidia (laboratory strain 3153A) were incubated for 30 min at 37°C with either an Fc{gamma}R1-expressing epithelial cell line, Fc{gamma}R1/CV-1, or its parental line, FRT/CV-1 (Gibco Invitrogen, Carlsbad, Calif.), at a blastoconidia/host cell ratio of 10:1. Fc{gamma}R1/CV-1 cells bound live Candida blastoconidia opsonized with either pIgG or scFv{lambda}2-18, but not unopsonized or scFv5-opsonized organisms (Fig. 1A). Because there was no difference in binding levels of unopsonized and scFv5-opsonized organisms, potential contaminants in the scFv preparations did not affect binding. No differences in binding were observed with live and heat-killed blastoconidia (data not shown), suggesting that C. albicans does not actively evade opsonization or degrade the opsonizing complex.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. scFv{lambda}2-18 targets C. albicans to FcR and mediates phagocytosis. (A) Fc{gamma}R1-expressing epithelial cells (Fc{gamma}R1/CV-1) or the parental cells (FRT/CV-1) were incubated with C. albicans strain 3153A blastoconidia opsonized as indicated. Cells that bound three or more blastoconidia were scored as positive (rosette formation). The mean percentage of cells forming rosettes ± standard error is plotted. scFv5, which does not recognize blastoconidia, was included as a mock opsonin. Anti-C. albicans pIgG- or scFv{lambda}2-18-opsonized organisms were bound at a significantly higher level (P < 0.001 for all comparisons) than unopsonized or mock-opsonized organisms. There was no significant difference between the levels of binding of unopsonized or mock-opsonized organisms (P = 0.212). (B) Photomicrographs of THP-1 cells incubated with C. albicans strain 3153A blastoconidia, opsonized as indicated, demonstrating extracellular (orange) and intracellular (green) blastoconidia. The white bar represents 10 µm. (C) Mean percentage of THP-1 cells completing phagocytosis ± standard error of C. albicans strain 3153A blastoconidia, opsonized as indicated. The levels of phagocytosis of pIgG- or scFv{lambda}2-18-opsonized organisms were not significantly different (P = 0.271); however, the levels of phagocytosis of either scFv{lambda}2-18-or pIgG-opsonized organisms, compared to those of unopsonized or mock-opsonized organisms (P < 0.001 for all comparisons), were significantly different.

For phagocytosis assays, cells of a human monocytic cell line, THP-1 (American Type Culture Collection, Manassas, Va.) (23-25) were incubated with Candida as described above, except that the sample was incubated for 30 min at 4°C prior to the 37°C incubation to develop a synchronized pool of host cells with membrane-bound organisms. Surface-bound organisms were distinguished by labeling blastoconidia with fluorescein isothiocyanate (FITC) prior to opsonization and subsequently adding ethidium bromide (EtBr) to the sample prior to microscopic analysis. EtBr, which is excluded from live host cells and, therefore, internalized organisms, stains external organisms, causing them to fluoresce orange (Fig. 1B). Heat-killed organisms were used because live organisms concentrate FITC in their vacuole, which is subsequently protected from EtBr staining. No difference in the level of phagocytosis of live versus heat-killed organisms was observed in pilot studies (data not shown).

The efficiency of phagocytosis was significantly enhanced by antibody opsonization (Fig. 1C). The scFv{lambda}2-18 complex mediated phagocytosis equivalently to mature antibody. The low level of phagocytosis seen with unopsonized or mock-opsonized organisms suggests that neither alternative receptors, such as mannose receptors, nor contaminants from the scFv preparation enhance phagocytosis under these conditions. This is consistent with a recent study in which mannose receptor-deficient mice were not found to have increased mortality from Candida infections (12).

Phagocytosis assays were conducted with seven C. albicans isolates and four non-albicans species (Table 1). Except for one clinical strain of C. albicans (MRO4-O), there was significant enhancement of phagocytosis when organisms were opsonized. Although differences in the level of phagocytosis of various organisms were observed, these differences were relatively small compared to the large increase in the level of phagocytosis associated with opsonization.


View this table:
[in this window]
[in a new window]
  		TABLE 1. scFv {lambda}2-18 mediates phagocytosis of various C. albicans strains and multiple Candida species by THP-1 cells

Because strain MRO4-O was efficiently ingested when opsonized with pIgG, but not scFv{lambda}2-18 (Table 1), we performed an immunofluorescence assay to investigate scFv{lambda}2-18 cognate antigen expression in this strain (Fig. 2A). Both pIgG and scFv{lambda}2-18 recognize Candida blastoconidia and filaments of strain 3153A with a diffuse, bright staining pattern (2, 7). In strain MRO4-O, this pattern was observed with pIgG but not scFv{lambda}2-18, which recognized only the point of elongation (Fig. 2A). Because stationary-growth-phase blastoconidia were used in the phagocytosis assays, strain MRO4-O blastoconidia would not have been effectively opsonized. When the phagocytosis assay was repeated by using blastoconidia that had been cultured for 1 h in medium M199 (Gibco), which allows development of nascent filaments, a significantly higher level of phagocytosis was observed (Fig. 2B and C). Furthermore, host cells that partially ingested filaments, causing exclusion of EtBr (Fig. 2C, top), or that ingested relatively large filaments (Fig. 2C, bottom) were observed.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 2. scFv{lambda}2-18 recognizes C. albicans strain MR04-O at the point of elongation and mediates phagocytosis of organisms with nascent germ tube growth. (A) Immunofluorescence assays of C. albicans strain MRO4-O performed with pIgG (detected by BODIPY FL-conjugated goat anti-rabbit antibody [Molecular Probes, Eugene, Oreg.]) or scFv{lambda}2-18 (detected by M2 anti-FLAG antibody and BODIPY FL-conjugated goat anti-mouse antibody [Molecular Probes]) demonstrate that scFv{lambda}2-18 recognizes only the area at the point of elongation. (B) Phagocytosis assays using scFv{lambda}2-18-opsonized blastoconidia (stationary growth) or scFv{lambda}2-18-opsonized nascent germ tubes were performed with C. albicans strains 3153A and MRO4-O. The mean percentage of phagocytosis ± standard error is plotted in panel B. (C) Fluorescence photomicrographs of THP-1 cells that had ingested organisms from the nascent growth sample of strain MRO4-O. The white bars in panels A and C represent 10 µm.

To verify that antibody opsonization could enhance phagocytosis in native human phagocytes, human monocytes and neutrophils that were obtained through an institutionally approved protocol were assayed as described above. Blood was drawn from healthy adult volunteers; monocytes were isolated with the RosetteSep monocyte enrichment system (StemCell Technologies, Vancouver, British Columbia, Canada), and neutrophils were isolated with the 1-Step Polymorphs system (Accurate Chemical, Inc.). Monocyte preparations contained 98% monocytes, and neutrophil preparations contained >99% neutrophils with no cross-contamination of cell types.

Phagocytosis by ex vivo monocytes obtained from two different donors (Fig. 3A) occurred in 40 to 50% of cells. The level of phagocytosis was significantly enhanced by opsonization in monocytes from donor A; however, cells from donor B demonstrated a high level of phagocytosis of both opsonized and unopsonized organisms. This donor-related discrepancy could be due to the monocyte activation state: Marodi et al. demonstrated that activated monocyte-derived macrophages did not require opsonization for phagocytosis, whereas unactivated monocytes did (15).



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 3. Ex vivo human phagocytes ingest C. albicans blastoconidia opsonized with scFv {lambda}2-18. (A) Peripheral blood monocytes were obtained from two different donors and assayed for phagocytosis with blastoconidia opsonized with scFv {lambda}2-18 or scFv 5, as indicated. THP-1 cells were assayed in parallel for comparison. The mean percentage of phagocytosis ± standard error is plotted. There was a significant increase in the level of phagocytosis of opsonized versus mock-opsonized blastoconidia for donor A (P < 0.001) but not for donor B (P = 0.127). (B) Neutrophils (PMN) were obtained from a single donor (donor B) on 2 different days (indicated as PMN-A and PMN-B) and assayed for phagocytic activity. For both samples, there was a significant increase in the level of phagocytosis of opsonized versus mock-opsonized organisms (P < 0.001).

The ex vivo neutrophils, which were obtained in independent experiments from the same donor, demonstrated a significant increase in the level of phagocytosis of opsonized organisms (Fig. 3B). The ex vivo phagocytes did not undergo phagocytosis at the level of the THP-1 cells, although the observed level of 25 to 50% is similar to those in other investigations with human phagocytes (17, 22). The ex vivo phagocytes are likely to be heterogeneous in FcR expression and activation state, which may have contributed to the lower level of phagocytosis compared with THP-1 cells.

The majority of studies investigating the phagocytosis of Candida have used fresh serum as an opsonizing agent (10, 15, 17, 19, 22). In their study on the protective monoclonal antibody B6.1, Caesar-TonThat and Cutler found that fresh serum was necessary for optimal organism killing (4). Herein, we demonstrated that specific antibody opsonization dramatically increases the level of phagocytosis in the absence of complement. Furthermore, scFv{lambda}2-18 functions as a Candida binding ligand equivalent to specific pIgG. Thus, scFv{lambda}2-18 is an important tool for studying the phagocyte response to Candida because it functions as an opsonin for many Candida species. Native antibody responses, which are complex and may not confer protection (3), may not adequately enhance phagocytosis. Because the antibody fragments tested in these studies are of human origin, they may provide the basis for future antibody prophylaxis or therapy for Candida infections.


arrow
ACKNOWLEDGMENTS
 
We thank Jacob J. Schlesinger and Clark L. Anderson for for the Fc{gamma}R1/CV-1 cell line and Lani A. Sherrill for technical expertise.

This work was supported by the Wilmot Cancer Research Fellowship (M.W.), University of Rochester Medical Center, Rochester, N.Y., and by National Institutes of Health grant T32 AI07464 (M.W. and J.B.).

The studies presented in this article will be submitted as a partial fulfillment of the requirements for the Doctor of Philosophy degree in Microbiology and Immunology for M.W.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave., Box 672, Rochester, NY 14642. Phone: (585) 275-0678. Fax: (585) 473-9573. E-mail: haid{at}mail.rochester.edu. Back

Editor: T. R. Kozel

{dagger} Present address: Department of Pediatrics, Women and Infants' Hospital of Rhode Island, Brown University School of Medicine, Providence, RI 02905. Back


arrow
REFERENCES
 
    1
  1. Bazzoni, F., M. A. Cassatella, C. Laudanna, and F. Rossi. 1991. Phagocytosis of opsonized yeast induces tumor necrosis factor-alpha mRNA accumulation and protein release by human polymorphonuclear leukocytes. J. Leukoc. Biol. 50:223-228.[Abstract]
    2. 2
  2. Bliss, J. M., M. A. Sullivan, J. Malone, and C. G. Haidaris. 2003. Differentiation of Candida albicans and Candida dubliniensis by using recombinant human antibody single-chain variable fragments specific for hyphae. J. Clin. Microbiol. 41:1152-1160.[Abstract/Free Full Text]
    3. 3
  3. Bromuro, C., A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, and A. Cassone. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462-5470.[Abstract/Free Full Text]
    4. 4
  4. Caesar-TonThat, T.-C., and J. E. Cutler. 1997. A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun. 65:5354-5357.[Abstract]
    5. 5
  5. Caron, E., and A. Hall. 1998. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282:1717-1721.[Abstract/Free Full Text]
    6. 6
  6. Ehlers, M. R. 2000. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2:289-294.[CrossRef][Medline]
    7. 7
  7. Haidaris, C. G., J. Malone, L. A. Sherrill, J. M. Bliss, A. A. Gaspari, R. A. Insel, and M. A. Sullivan. 2001. Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens. J. Immunol. Methods 257:185-202.[CrossRef][Medline]
    8. 8
  8. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.[Abstract]
    9. 9
  9. Han, Y., and J. E. Cutler. 1997. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis. 175:1169-1175.[Medline]
    10. 10
  10. Kagaya, K., and Y. Fukazawa. 1981. Murine defense mechanism against Candida albicans infection. II. Opsonization, phagocytosis, and intracellular killing of C. albicans. Microbiol. Immunol. 25:807-818.[Medline]
    11. 11
  11. Kipriyanov, S. M., G. Moldenhauer, and M. Little. 1997. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J. Immunol. Methods 200:69-77.[CrossRef][Medline]
    12. 12
  12. Lee, S. J., N.-Y. Zheng, M. Clavijo, and M. C. Nussenzweig. 2003. Normal host defense during systemic candidiasis in mannose receptor-deficient mice. Infect. Immun. 71:437-445.[Abstract/Free Full Text]
    13. 13
  13. Levitz, S. M. 1992. Overview of host defenses in fungal infections. Clin. Infect. Dis. 14(Suppl. 1):S37-S42.
    14. 14
  14. Malone, J., and M. A. Sullivan. 1996. Analysis of antibody selection by phage display utilizing anti-phenobarbital antibodies. J. Mol. Recognit. 9:738-745.[CrossRef][Medline]
    15. 15
  15. Marodi, L., H. M. Korchak, and R. B. Johnston, Jr. 1991. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J. Immunol. 146:2783-2789.[Abstract]
    16. 16
  16. Marr, K. A. 2000. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr. Opin. Infect. Dis. 13:615-620.[Medline]
    17. 17
  17. Newman, S. L., and A. Holly. 2001. Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect. Immun. 69:6813-6822.[Abstract/Free Full Text]
    18. 18
  18. Odds, F. C. 1988. Candida and candidosis, 2nd ed. Baillière Tindall, London, United Kingdom.
    19. 19
  19. Pereira, H. A., and C. S. Hosking. 1984. The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin. Exp. Immunol. 57:307-314.[Medline]
    20. 20
  20. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, R. J. Hollis, and The SENTRY Participant Group. 2000. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751.[Abstract/Free Full Text]
    21. 21
  21. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, and R. P. Wenzel. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn. Microbiol. Infect. Dis. 30:121-129.[CrossRef][Medline]
    22. 22
  22. Richardson, M. D., and F. Donaldson. 1994. Interaction of Candida krusei with human neutrophils in vitro. J. Med. Microbiol. 41:384-388.[Abstract/Free Full Text]
    23. 23
  23. Stokes, R. W., and D. Doxsee. 1999. The receptor-mediated uptake, survival, replication, and drug sensitivity of Mycobacterium tuberculosis within the macrophage-like cell line THP-1: a comparison with human monocyte-derived macrophages. Cell Immunol. 197:1-9.[CrossRef][Medline]
    24. 24
  24. Suzuki, T., N. Ohno, Y. Ohshima, and T. Yadomae. 1998. Soluble mannan and beta-glucan inhibit the uptake of Malassezia furfur by human monocytic cell line, THP-1. FEMS Immunol. Med. Microbiol. 21:223-230.[Medline]
    25. 25
  25. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171-176.[Medline]
    26. 26
  26. van Spriel, A. B., I. E. van den Herik-Oudijk, N. M. van Sorge, H. A. Vile, J. A. van Strijp, and J. G. van de Winkel. 1999. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. J. Infect. Dis. 179:661-669.[CrossRef][Medline]
    27. 27
  27. Vázquez-Torres, A., and E. Balish. 1997. Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. 61:170-192.[Abstract]
    28. 28
  28. Walsh, T. J., C. Gonzalez, E. Roilides, B. U. Mueller, N. Ali, L. L. Lewis, T. O. Whitcomb, D. J. Marshall, and P. A. Pizzo. 1995. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin. Infect. Dis. 20:900-906.[Medline]

Infection and Immunity, December 2003, p. 7228-7231, Vol. 71, No. 12
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.12.7228-7231.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodrigo, W. W. S. I., Jin, X., Blackley, S. D., Rose, R. C., Schlesinger, J. J. (2006). Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc{gamma}RIA (CD64) or Fc{gamma}RIIA (CD32).. J. Virol. 80: 10128-10138 [Abstract] [Full Text]  
  • Zhang, M. X., Bohlman, M. C., Itatani, C., Burton, D. R., Parren, P. W. H. I., St. Jeor, S. C., Kozel, T. R. (2006). Human Recombinant Antimannan Immunoglobulin G1 Antibody Confers Resistance to Hematogenously Disseminated Candidiasis in Mice. Infect. Immun. 74: 362-369 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wellington, M.
Right arrow Articles by Haidaris, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wellington, M.
Right arrow Articles by Haidaris, C. G.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»